Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of “Moderate Buy” by Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $30.55.

Several equities research analysts recently weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Piper Sandler increased their target price on Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. Sanford C. Bernstein started coverage on Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Roivant Sciences in a research note on Friday, May 8th.

Roivant Sciences Stock Down 0.7%

Shares of ROIV stock opened at $29.29 on Friday. The stock has a market cap of $20.96 billion, a price-to-earnings ratio of -25.03 and a beta of 1.14. The business’s fifty day moving average is $28.41 and its 200 day moving average is $24.68. Roivant Sciences has a twelve month low of $10.58 and a twelve month high of $30.33.

Insider Transactions at Roivant Sciences

In other news, Director Melissa B. Epperly sold 41,861 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the sale, the director directly owned 15,804 shares of the company’s stock, valued at approximately $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Monday, April 20th. The stock was sold at an average price of $29.59, for a total value of $5,918,000.00. Following the completion of the sale, the chief executive officer directly owned 1,647,546 shares in the company, valued at approximately $48,750,886.14. This represents a 10.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 3,745,173 shares of company stock valued at $103,639,917. 10.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. lifted its holdings in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Finally, Parallel Advisors LLC lifted its holdings in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after purchasing an additional 520 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.